HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma Review
| Authors: | Tabernero, J.; Shen, L.; Elimova, E.; Ku, G.; Liu, T.; Shitara, K.; Lin, X.; Boyken, L.; Li, H.; Grim, J.; Ajani, J. |
| Review Title: | HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma |
| Abstract: | HER2-positive gastroesophageal adenocarcinomas (GEAs) are common cancers with high mortality and the treatment options for advanced/metastatic disease are limited. Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA. Preliminary data suggest that dual targeting of the HER2 and PD-1 pathways could further improve upon the results achieved with targeting either pathway alone. Here, we describe the design of HERIZON-GEA-01, a global, randomized, open-label, active-comparator, Phase III study to evaluate and compare the efficacy and safety of zanidatamab plus chemotherapy with or without tislelizumab to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for patients with advanced/metastatic HER2-positive GEAs. HERIZON-GEA-01: A phase III study of zanidatamab + chemotherapy ± tislelizumab for first-line treatment of advanced or metastatic #HER2-positive gastroesophageal adenocarcinoma (GEA). Clinicaltrials.gov: NCT05152147. #gastriccancer #stomachcancer @ZymeworksInc @BeiGeneGlobal Clinical Trial Registration: NCT05152147 (ClinicalTrials.gov). |
| Keywords: | genetics; antineoplastic agents; antineoplastic agent; adenocarcinoma; metabolism; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; pathology; monoclonal antibody; antibodies, monoclonal; receptor, erbb-2; trastuzumab; esophageal adenocarcinoma; stomach neoplasms; esophagus tumor; esophageal neoplasms; stomach tumor; her2; human epidermal growth factor receptor 2; gastric cancer; esophagogastric junction; programmed death 1 receptor; gastroesophageal junction cancer; gastroesophageal adenocarcinoma; gastroesophageal junction; antibodies, monoclonal, humanized; humans; human; programmed cell death 1 receptor; pd-1/pd-l1 inhibitor; gea; tislelizumab; zanidatamab |
| Journal Title: | Future Oncology |
| Volume: | 18 |
| Issue: | 29 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2022-09-01 |
| Start Page: | 3255 |
| End Page: | 3266 |
| Language: | English |
| DOI: | 10.2217/fon-2022-0595 |
| PUBMED: | 36000541 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 November 2022 -- Source: Scopus |
